Chronic Beryllium Disease: What to Do When Initial Oral Prednisone Leads to Clinical Relapse

This protocol addresses the management of chronic beryllium disease at a specific clinical juncture: when the patient has already received a first course of oral prednisone and is now experiencing a short-term clinical relapse — signalling that the initial approach has not sustained adequate disease control.

Why this protocol is triggered

First-line therapy with oral prednisone failed to achieve or maintain its intended goals: meaningful improvement in forced vital capacity (FVC), improvement in diffusing capacity for carbon monoxide (DLCO), and a reduction in the active lesion score on high-resolution CT of the chest. Clinical relapse in this context is the defined trigger for escalation to the current protocol.

Treatment approach (partial overview)

When short-term clinical relapse is identified, the structured approach involves a targeted adjustment to the oral corticosteroid regimen — specifically at the level of dosing. The complete criteria, decision points, and follow-up framework are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1080/15459620903158698

Increase in dose of oral corticosteroids ensured clinical improvement in all short-term clinical relapses in the Marchand-Adam study.
Evidence of short-term clinical relapse merits dose escalation.

View source ↗